Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Suzhou Junmeng Biosciences Co. Ltd. operates within the Biotechnology & Pharmaceuticals technology area, currently managing 1 pending office action. This matter is being reviewed by 1 distinct examiner, indicating a narrow front for current patent prosecution. The portfolio's active cases are confined to 1 distinct art unit, which is typical for specialized biological innovations requiring specific technical expertise.
The busiest examiner for this portfolio is BUTTICE, AUDREY L, who is currently responsible for 1 busiest examiner pending office action. This examiner represents the entirety of the company's current interaction with the patent office's examining corps. For the applicant, this means that the immediate future of their intellectual property in this sector depends on the specific interpretations and requirements of BUTTICE, AUDREY L.
In the complex field of Biotechnology & Pharmaceuticals, having 1 distinct examiner and 1 distinct art unit can simplify the legal strategy by allowing for a highly targeted approach. Practitioners should prepare for a focused dialogue with BUTTICE, AUDREY L to ensure that the technical nuances of the bioscience claims are clearly communicated. Successful resolution of the 1 pending office action is essential for the portfolio's growth.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276639 | ANTI-CD112R ANTIBODY AND USE THEREOF | BUTTICE, AUDREY L | 34d |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18276639 | ANTI-CD112R ANTIBODY AND USE THEREOF | BUTTICE, AUDREY L | 1647 | §112 | Non-Final OA | 34d | Pending | Aug 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial